La Jolla Pharmaceutical Company (LJPC) 2003年年度报告「NASDAQ」.pdf

1、Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,DC 20549FORM 10-KFOR ANNUAL AND TRANSITION REPORTSPURSUANT TO SECTIONS 13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934 X ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year

2、 ended DECEMBER 31,2003OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _Commission file number:0-24274LA JOLLA PHARMACEUTICAL COMPANY(Exact Name of Registrant as Specified in Its Charter)Delaware(State or Other Jurisdicti

3、onof Incorporation of Organization)33-0361285(I.R.S.EmployerIdentification No.)6455 Nancy Ridge Drive,San Diego,CA 92121(Address of Principal Executive Offices,including Zip Code)Registrants telephone number,including area code:(858)452-6600 Securities registered pursuant to Section 12(b)of the Act:

4、None Securities registered pursuant to Section 12(g)of the Act:Common Stock,par value$0.01 per share Indicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Actof 1934 during the preceding 12 months(or for such shor

5、ter period that the registrant was required to file such reports),and(2)has been subject tosuch filing requirements for the past 90 days.Yes X No Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein,and will not becontained,to the b

6、est of registrants knowledge,in definitive proxy or information statements incorporated by reference in Part III of the Form 10-Kor any amendment to this Form 10-K.Indicate by check mark whether the registrant is an accelerated filer(as defined in Exchange Act Rule 12b-2).Yes X No The aggregate mark